January 21st, 2025 | 07:30 CET
Bayer awakened! BioNxt Solutions, Novo Nordisk – Invest in tomorrow's winners today
The economy is at a turning point, as the rapid advancements in artificial intelligence are enabling technological innovations that set new benchmarks. Revolutionary developments are emerging, particularly in the pharmaceutical industry, medical technology, and biotechnology. These sectors not only unlock groundbreaking medical possibilities but also offer significant economic growth potential. Investors who move in early to disruptive technologies or dynamic growth industries can count on attractive returns. But which players are dominating this wave of innovation? And how can you, as an investor, benefit strategically? A closer look is worthwhile.
time to read: 4 minutes
|
Author:
Armin Schulz
ISIN:
BAYER AG NA O.N. | DE000BAY0017 , Bionxt Solutions Inc. | CA0909741062 , NOVO NORDISK A/S | DK0062498333
Table of contents:
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
Tag cloud
Shares cloud
Bayer – New momentum after hard times?
Bayer shares appear to be recovering slowly from a long-term downward trend that has seen them lose over 80% of their value since 2015. This development is due to innovations in the pharmaceutical division. With new drugs such as the prostate cancer drug Nubeqa and other new preparations such as Kerendia or Elinzanetant, the Leverkusen-based company has a strong pipeline. This could offset lost sales from the expiration of patents on established products such as the blood thinner Xarelto, ensuring long-term growth.
Even though the agriculture division continues to face challenges – particularly from price pressure and declining glyphosate sales – Bayer is trying to break new ground with strategic partnerships, such as the recent collaboration with Neste. In doing so, the Company is focusing on solutions that are more sustainable and diversified. In the long term, these measures could strengthen the agricultural sector and make it less dependent on traditional crop protection products. Nevertheless, uncertainties remain, particularly due to the legal disputes.
In addition to the lawsuits, the Monsanto acquisition is a burden for the Company, as it incurred high debts at the time to finance the acquisition. Currently, net financial debt amounts to EUR 35 billion. However, with restructuring and efficiency programs under the new "Dynamic Shared Ownership" approach, Bayer is showing progress that could get the Company back on track in the long term. Bayer recently announced that the restructuring is well on schedule. The share has formed a double bottom at around EUR 18.70 and is currently trading at EUR 21.05.
BioNxt Solutions - Exciting advances in biotechnology
The Canadian biotechnology company BioNxt Solutions specializes in advanced drug delivery systems. The focus is on the development of patient-friendly therapies that not only work more efficiently but also make patients' daily lives easier. At the beginning of December, the Company announced the development of a sublingual film with the active ingredient semaglutide under the name BNT24005. Semaglutide, which is known for treating type 2 diabetes and obesity, could be made even easier for patients to take, thanks to BioNxt's new delivery system. At the same time, the orodispersible film product BNT23001, which is specifically designed for the treatment of multiple sclerosis (MS), is making progress.
On 19 September, the Company announced that it had extended the patent protection for its drug delivery systems after the International Preliminary Report on Patentability (IPRP) of the European Patent Office found the Company's underlying technologies to be patentable. Corresponding applications have been filed in the US, Canada, Europe and Japan. CEO Hugh Rogers commented: "Securing robust intellectual property rights in key markets is a critical part of our strategy to provide innovative, patient-friendly therapies to people affected by autoimmune neurodegenerative diseases."
The Company has ambitious plans for 2025. The sublingual formulation of cladribine for MS is to be investigated in clinical trials. In addition, the pipeline is to be expanded, and new strategic partnerships are to be entered into with pharmaceutical and biotech companies. To achieve the latter, management will be present at major global conferences. The year has started well. The Company has raised CAD 3 million through unsecured convertible bonds that bear interest at 8%. The funds will be used to advance the development of the product pipeline and optimize innovative formulations such as sublingual thin films and skin patches. The share price has almost doubled in recent months and is currently trading at CAD 0.40.
Novo Nordisk – Steady growth through innovation
The Danish company Novo Nordisk is a textbook example of success in the healthcare sector. With a clear focus on patient-centred solutions and an impressive track record of innovation, the Company has consolidated its market position as a global leader. For a long time, the Company was considered an insulin manufacturer, but with obesity therapy, it now has another blockbuster in its portfolio. Even though the latest studies only led to an average weight reduction of 20.7% at a higher dosage of semaglutide, it is still a significant improvement over the standard dosage.
Novo Nordisk is relying on collaborations to further expand its development pipeline. A partnership with Valo Health is set to revolutionize research using artificial intelligence. The aim is to develop new treatments for chronic diseases such as obesity and type 2 diabetes. Up to 20 programs are planned that should significantly increase efficiency in drug development. These strategic alliances underpin the Company's intention to optimize scientific methods with new methods in order to obtain faster results.
Despite all these achievements, Novo Nordisk is facing regulatory hurdles. The inclusion of key drugs in the Medicare price control system in the US has put pressure on the share price. At the same time, competition in the obesity market is intensifying, with companies such as Eli Lilly entering the fray. However, forward-looking, long-term research and technological advances should ensure that Novo Nordisk remains well-positioned to continue to grow in a competitive market environment. The share price has lost almost 50% from its high and is trading at USD 78.69. Interested investors should wait for the share price to stabilize before entering the market.
Investors who want to focus on innovation and progress could find rewarding prospects in Bayer, BioNxt Solutions, and Novo Nordisk. Bayer is showing potential for stabilization after challenging years with new drugs, but remains burdened by the Monsanto takeover and legal disputes. The biotechnology company BioNxt Solutions scores with innovative drug delivery systems and secures patents to protect its intellectual property. Novo Nordisk remains a model company despite regulatory challenges and competition thanks to insulin, obesity therapy, and AI-supported research.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
